Further, significantly higher numbers of CTCs could be detected using an EpCAM independent detection method compared to EpCAM based enrichment technology (69.2% vs. 42.3%) in breast cancer patients[32], suggesting that a mixture of EpCAM positive and EpCAM negative tumour cells circulate in the blood. This evidence concerns the gene EPCAM and neoplasm.